Preview

Ожирение и метаболизм

Расширенный поиск

Неалкогольная жировая болезнь печени: актуальные проекты

https://doi.org/10.14341/2071-8713-5155

Полный текст:

Об авторах

С. А. Бутрова

Эндокринологический научный центр, Москва


Россия


А. Ю. Елисеева

Эндокринологический научный центр, Москва


Россия


Список литературы

1. Богомолов П.О., Шульпекова Ю.О. Неалкогольная жировая болезнь печени: стеатоз и неалкогольный стеатогепатит. Клинические перспективы гастроэнтерологии, гепатологии. 2004;3:20-6.

2. Буеверов А.О., Маевская М.В. Некоторые патогенетические и клинические вопросы неалкогольного стеатогепатита. Клинические перспективы гастроэнтерологии, гепатологии. 2003;3:2-7.

3. Bailey C.I., Turner R.C. et al. Metformin. N Engl J Med. 1996;334:574-9.

4. Browning J., Szczepaniak L, Dobbins R. et al. Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity. Hepatology. 2004;40:1387-95.

5. Bugianesi E., Gastaldelli A., Vanni E. et al. Insulin resistance in non- diabetic patients with nonalcoholic fatty liver disease:sites and mechanisms. Diabetogia. 2005;48:634-42.

6. Bugianesi E., Pagotto U., Manini R. et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90:3498-504.

7. Chalasani N., Crabb D., Cummings O. et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol. 2003;98:2771-6.

8. Charles M., Morange P., Eschwege E. et al. Effect of weight change and metformin on fibrinolisis and the von Willebrand factor in obese nondiabetic subjects. Diabetes care 1998;21:1967-72.

9. Day C., James O. Steatohepatitis:a tale of two «hits»? Gastroenterology. 1998;14:842-5.

10. Houmard J., Tanner C., Slentz C. et al. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol. 2004;96:101-6.

11. Huang M.A., Greenson J.K., Chao C. et al. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis:a pilot study. Am J Gastroenterol. 2005;100:1072 -81.

12. Hui J.M., Hodge A., Farrell G.C. et al. Beyond insulin resistance in NASH: ФНО-alpha or adiponectin? Hepatology. 2004;40:46-54.

13. Kern P.A., Ranganathan S., Li C. et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745-5.

14. Kugelmas M., Hill D.B., Vivian B. et al. Cytokines and HASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-9.

15. Lam T.K., Caspentier A. et al. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metabol. 2003;284:E863 73.

16. Lin H.Z., Yang S.Q., Chuckaree C. et al. Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med 2000;6:998-1003.

17. Longo R., Pollesello P., Ricci C. et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging. 1995;5:281-5.

18. Ludwig J. et al. Nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 1997;12:398-403.

19. Luyckx F.H., Desaive C., Thiry A. et al. Liver abnormalities in severely obese subjects:effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222-6.

20. Marchesini G., Brizi M., Bianchi G., Tomasetti S., Zoli M., Melachionda N. еt al. Nonalcoholic fatty liver disease:a feature of the metabolic syndrome. Diabetes. 2001;50:1844-50.

21. Marchesini G., Brizi M., Morselli-Labate A. M. et al. Association of nonalcogolic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-5.

22. Marchesini G., Bugianesi E., Forlani G. et al. Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology. 2003;37:917-23.

23. Miyazaki Y., Glass L., Triplitt C. et al. Effect of rosiglitazone on glucose and none-sterified fatty acid metabolism in Type II diabetic patients. Diabetologia. 2001;44:2210-9.

24. Miyazaki Y., Mahankali A., Matsuda M. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784-91.

25. Moghetti P., Castello R., Negry C. et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome:a randomized, double- blind, placebo-controlled 6-month trial, followed by open, long term clinical evalution. J Clin Endocrinol Metab. 2000;85:139-46.

26. Mottin C.C., Moretto M., Padoin A.V. et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004;14:635-7.

27. Nair S., Diehl A.M., Wiseman M. et al. Metformin in the triement of non-alcoholic steatohepatitis:a pilot open label trial. Aliment Pharmacol Ther. 2004;20:23-8.

28. Nicklas B.J., Penninx B.W., Ryan A.S. et al. Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. Diabetes Care. 2003;26:1413-20.

29. Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408-13.

30. Samuel V. T., Liu Z. X., Qu X. et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345-53.

31. Seppala-Lindross A., Vehkavaara S., Hakkinen A. M., Goto T., Westerbacka J., Sovijatvi A., Halavaara J., Yki-Jarvinen H. Fat accumulation on the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87:3023-8.

32. Solomon S.S., Mishra S.K., Cwik C. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab. Res. 1997;29:370-82.

33. Tessier D., Maheux P., Khalil A. et al. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism. 1999;29:370-82.

34. Tiikkainen M., Hakkinen A.M., Korsheninnikova E. et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169-76.

35. Uygun A., Kadayifci A., Yesilova Z. et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2000;95:3584-9.

36. Virtanen K., Hallsten K., Parkkola R. et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subject. Diabetes. 2003;52:283-90.

37. Wolfrum C., Asilmaz E., Luca E. et al. Foxa 2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature. 2004;432:1027-32.

38. Yahagi N., Shimano H., Hasty A.H., Matsuzaka T. et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep (ob)/Lep(ob) mice. J Biol Chem. 2002;277:19353-7.

39. Yamauchi T., Kamon J., Minokoshi Y. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-1895.


Рецензия

Для цитирования:


Бутрова С.А., Елисеева А.Ю. Неалкогольная жировая болезнь печени: актуальные проекты. Ожирение и метаболизм. 2007;4(2):2-7. https://doi.org/10.14341/2071-8713-5155

For citation:


Butrova S.A., Eliseeva A.Yu. Nealkogol'naya zhirovaya bolezn' pecheni: aktual'nye proekty. Obesity and metabolism. 2007;4(2):2-7. (In Russ.) https://doi.org/10.14341/2071-8713-5155

Просмотров: 209


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)